Nutrien (NTR) Price Target Raised to $65 at Morgan Stanley

Nutrien Ltd. (NYSE:NTR) is one of the 10 best organic food and farming stocks to buy now. On June 26, Morgan Stanley analyst Vincent Sinisi reiterated an Equal-Weight rating on the stock. Similarly, the analyst raised his price target to $65 from $60.

Nutrien (NTR) Price Target Raised to $65 at Morgan Stanley

A farmer in an agricultural field, harvesting crops enhanced with improved traits.

The adjustment underscores a positive outlook on Nutrien growth prospects and stock’s performance. In addition, the bullish stance is driven by Nutrien’s retail segment, which showed resilience and delivered strong performance, helping offset weakness in other areas.

The leading provider of crop inputs and services has also recorded growth in its potash segment, which has outperformed expectations. Nutrien’s focus on buybacks and retail tuck-in acquisitions also affirm smart capital allocation.

Nutrien Ltd. (NYSE:NTR) is one of the top farm stocks, serving as a global provider of crop inputs and services. It offers farmers a range of solutions to enhance crop production. It is the world’s largest producer of potash and the third-largest producer of nitrogen. While Nutrien doesn’t produce organic food directly, it supports both conventional and organic farming by offering soil health products and sustainable crop management solutions. Nutrien has been featured on lists of top organic food and farming stocks due to its strategic importance in global agriculture and its exposure to trends like regenerative and organic farming.

While we acknowledge the potential of NTR to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NTR and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 13 Best Blue Chip Stocks to Buy According to Analysts and 10 Most Undervalued Gold Stocks to Buy According To Analysts.

Disclosure: None. This article is originally published at Insider Monkey.